The use of embryonic stem cells to develop medical treatments is a controversial topic. Michael Factor and Moshe Tritel look at the situation in Israel.
The use of embryonic stem cells to develop medical treatments is a controversial topic. Michael Factor and Moshe Tritel look at the situation in Israel.
Embryonic stem cells are extracted from a blastocyt—a fertilised human ovule that is four or five days old. These stem cells can develop into different kinds of cells and are the subject of research that promises novel treatments, cures and even the prevention of diseases. However, the process of extracting the cells kills the embryo. This raises fundamental moral issues.
The Israel Patent Law 1967 does not discuss ordre public or morality. All technologies are patentable under the law, except for Section 7, which excludes from patentable subject matter:
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Patentability, ethical considerations, Israel, stem cell research, human genome
